Elevance Health, Inc. $ELV Holdings Lowered by Barrow Hanley Mewhinney & Strauss LLC

Barrow Hanley Mewhinney & Strauss LLC lessened its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 14.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 497,340 shares of the company’s stock after selling 83,828 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned about 0.22% of Elevance Health worth $160,701,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vestmark Advisory Solutions Inc. purchased a new stake in shares of Elevance Health during the second quarter valued at $730,000. Prospera Financial Services Inc boosted its holdings in shares of Elevance Health by 335.0% in the second quarter. Prospera Financial Services Inc now owns 5,412 shares of the company’s stock worth $2,107,000 after buying an additional 4,168 shares during the period. Los Angeles Capital Management LLC increased its position in shares of Elevance Health by 354.7% in the second quarter. Los Angeles Capital Management LLC now owns 5,156 shares of the company’s stock worth $2,005,000 after acquiring an additional 4,022 shares in the last quarter. Midwest Trust Co purchased a new stake in shares of Elevance Health in the 2nd quarter valued at approximately $627,000. Finally, Zions Bancorporation National Association UT boosted its stake in Elevance Health by 100.7% in the 2nd quarter. Zions Bancorporation National Association UT now owns 604 shares of the company’s stock worth $235,000 after purchasing an additional 303 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Up 0.8%

ELV stock opened at $282.92 on Wednesday. The stock has a market capitalization of $62.44 billion, a price-to-earnings ratio of 11.26, a price-to-earnings-growth ratio of 1.55 and a beta of 0.51. The company has a 50-day moving average of $341.97 and a two-hundred day moving average of $334.91. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. Elevance Health’s dividend payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ELV shares. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Robert W. Baird upped their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Finally, Morgan Stanley decreased their target price on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 17th. Twelve equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.